Allergy immunotherapy Market By Product Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy {SLIT Tablets, SLIT Drops}, Oral Immunotherapy (OIT)), By Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Atopic Dermatitis, Venom Allergy), By End-User (Hospitals, Clinics, Homecare Setting), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles, And Market Forecast, 2025 – 2035

Industry Outlook

The Allergy Immunotherapy market accounted for USD 2.67 Billion in 2024 and is expected to reach USD 6.35 Billion by 2035, growing at a CAGR of around 8.2% between 2025 and 2035. The allergy immunotherapy market concentrates on the production and distribution of products to eliminate clients’ allergic reactions to specific precipitating agents. This market includes sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) used for treatments for allergic rhinitis, asthma, and food allergies.

SLIT is available in tablet or drop form and is therefore preferred over SCIT, which refers to regular allergy shots. The main drivers of the market are the growing incidence of allergies, improving awareness about treatments, the development of personalized medicine, and better accessibility to health care, particularly in the developing world.

Report Scope:

Market Dynamics

The rising incidence of respiratory and food allergies globally is boosting demand for effective Immunotherapies

The prevalence of respiratory and food allergies across the world heralds a public health issue and has been recognized as a direct determinant of global demand for the allergy immunotherapy market. Demographic changes, including growth in cities, pollution, and developmental changes, are making respiratory allergies, including rhinitis and asthma, more common. Likewise, food allergies, especially in children, have continually been on the rise, with the common allergic agents being peanuts, milk, and shellfish. These conditions affect the quality of life and impose a high cost on the health care systems and therefore call for the efficacy of long-term disease-modifying therapy such as AIT.

Immunotherapy is a successful method in which an allergist treats the cause of the allergy rather than the symptoms. It works by gradually desensitizing the body to allergens, and it provides long-term results that may also assist in preventing the development of other types of allergy illnesses. The number of allergy cases has increased, raising the awareness of AIT among patients and health practitioners. Furthermore, advances in AIT administration have resulted in new ways of delivery, such as sublingual immunotherapy (SLIT), making the treatment more tolerable and opening up commercial potential in a growing market.

Advancements in Sublingual Immunotherapy (SLIT), Convenient, non-invasive treatment methods like SLIT tablets are driving patient preference

Sublingual immunotherapy (SLIT) is the most recent breakthrough in the allergy immunotherapy sector, and it has the potential to be a more appealing alternative to subcutaneous immunotherapy (SCIT) due to its lack of injections. As a result, SLIT consists of allergen extracts supplied in tablets, drops, or sprays, making it convenient for patients to administer at home. This reduces the number of clinic visits needed, as is the case with allergy shots, enhancing patient compliance and general access. In addition to this, studies have shown SLIT has fewer incidences of side effects, such as systemic allergic reactions, than SCIT, and it is safer for kids or any severe allergic patients.

Simplification of treatment with the SLIT tablets developed for standard allergens such as grass pollen, house dust mites, and ragweed has also been beneficial. The need to obtain regulatory approvals and the evidence behind the effectiveness of SLIT tablets have paved the way to increased use in areas such as Europe, where SLIT is the favored substance. Flexible to use, SLIT dovetails perfectly with the latest patient-friendly lifestyle concerns, such as compliance with therapy and avoidance of injectable products; this assures continuous growth of the allergen immunotherapy market. This provides a significant growth opportunity for SLIT, as research continues to further the formalities and increase the application of the devices in coming years.

Allergy Immunotherapy remains expensive, limiting access for lower-income populations

The issue of limited access to the allergy immunotherapy market can be ascribed to the high costs of implementation. Another concern while giving AIT is the expense of the allergen extracts, which must be paired with the cost of ongoing healthcare visits to administer and manage AIT. Allergen-specific SQIT is typically provided over several years with frequent clinic visits, resulting in increased overall expenses. Furthermore, like with venom immunotherapy, sublingual immunotherapy (SLIT) tablets or drops are far less inconvenient and typically less expensive, but they are not adequately covered by insurance, so patients must pay out of pocket.

Because of the intricacy of manufacturing and healthcare delivery, AIT's cost model is determined by production and specialized healthcare providers. Allergen extracts must meet certain regulatory criteria, and tailoring procedures raise the cost of production. In developing countries, the lack of educated allergists raises costs because most patients must seek treatment in cities. Such budgetary restraints are especially expensive for low-income populations, even though allergy rates are rising worldwide. These problems must be addressed through regulatory measures, insurance development, and frugal innovations to ensure the future expansion of this sector and, more crucially, long-term patient outcomes around the world.

Advancements in genomics and diagnostics allow for tailored therapies, enhancing efficacy and adoption

Molecular diagnostics and genetic engineering are changing the nature of the allergy immunotherapy market by bringing in individualized strategies for treatment. Molecular genetic tools, NGS, give the doctor clues about how a particular patient’s immune response reacts to allergies and what genes predispose a person to the condition. These results help specialists adjust immunotherapy to further identify the optimal dosage and the duration of the process for each patient. Further, novel diagnostic techniques, which include component-resolved diagnostics (CRD), narrow down unique proteins that are contributing to sensitivity. This control means that immunotherapy presents the exact allergens, thus enhancing the effectiveness of treatment and minimizing side effects.

The combination of self-genomics with diagnostics also advances the introduction of fresh allergy immunotherapy products. The findings in the study can help pharmaceutical firms enhance the efficacy and safety of allergen extracts and formulations by providing genomic data. Individual programs are beneficial in improving patient compliance and in offering more possibilities of therapy for complicated cases of polysensitized patients who have an allergic reaction to several stimuli. As these technologies become more inexpensive, they will play a significant role in expanding the use of AIT, particularly in places where allergy rates are rising and traditional therapies have proven ineffective.

Untapped regions like Asia-Pacific and Latin America offer significant growth potential due to rising allergy cases and improving healthcare access

Asia-Pacific and Latin America are thought to be the most promising untapped areas in the allergy immunotherapy market. Factors contributing to growing allergy trends in Asia-Pacific include increased urbanization, pollution, and lifestyle changes. As a result, the general population is still unaware of the most recent treatment for allergic illnesses, allergen immunotherapy (AIT). Nonetheless, a weak health infrastructure, a lack of government measures to address chronic respiratory issues, and rising per capita income are boosting market growth. Some Asian countries, such as China, India, and Japan, are gradually shifting away from broad allergy treatments and toward more convenient options like SLIT.

The allergy immunotherapy market is booming in Latin America, where allergic illnesses have increased due to a variety of environmental variables such as high pollen levels and climate change. The region previously did not encourage AIT due to concerns with medical facilities, such as access and cost. However, continued growth in healthcare systems, combined with the arrival of new local regional competitors offering cheaper options, is gradually closing the gap. Emerging countries such as Brazil, Mexico, and Argentina are among the most advanced in terms of increasing investment in allergy diagnosis and treatment. Furthermore, the growth of other linked awareness initiatives and patient education services is expected to drive up demand for allergy immunotherapy services in these areas.

Industry Experts Opinion

“Immunotherapy, a preventative treatment, can be a lasting solution for those who are allergic to grass, trees, weed, dust, cats and dogs”

• Dr. Aujnarain, studied medicine at the University of Ottawa

Segment Analysis

Based on product type, the Allergy Immunotherapy Market is classified into Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. Subcutaneous immunotherapy (SCIT) is the largest and most important segment of the allergy immunotherapy market. SCIT has been the standard allergy treatment for many years, having been successfully used for patient desensitization. It requires employing steadily increasing concentrations of allergens to achieve permanent illness remission. SCIT has thus been the first line of treatment in allergy immunotherapy over the years since it is clinically accepted, efficacious, time-tested, and patient-compliant.

Based on allergy type, the Allergy Immunotherapy market is classified into Allergic Rhinitis, Asthma, Food Allergy, Atopic Dermatitis, and Venom Allergy. The allergic rhinitis section of the allergy immunotherapy market is the largest. The condition characterized as sensitivity to specific types of airborne particles, such as pollen, dust, or mold, affects a wide global population and has a high occurrence, particularly in large urban areas. They are frequent, and the frequency of environmental allergens is increasing, and there is likely a strong demand for immunotherapy solutions such as sublingual or subcutaneous immunotherapy. The persistent symptoms of allergic rhinitis drive a significant portion of market demand as people seek remedies for these illnesses. This makes it the largest segment in the allergy immunotherapy market right now.

Regional Analysis

The Europen Allergy Immunotherapy market is dominant due to the high usage rate of sublingual immunotherapy (SLIT) and the well-developed healthcare system. Leading players included Germany, France, and Italy, which have prevalent allergy illnesses and advanced regulatory processes for discovering and marketing novel medicines. The region benefits from increased research, development spending, and relationships between universities, pharmaceutical companies, and the healthcare industry. Awareness campaigns and reimbursement policies increase access to therapies and reimbursement rates. SLIT pills, in particular, have emerged as market leaders due to their ease of use and approval by European guidelines for the treatment of allergic disorders.

The Asia-Pacific allergy immunotherapy market is growing due to increased incidences of allergies, growth in urban areas, and exposure to pollution. China, India, and Japan are among the key sources of this growth because enhanced healthcare systems and increasing per capita income make hi-tech treatments affordable. These regions are unaware of allergen immunotherapy, but governments and private companies are steadily planning for its growth. The local manufacturers are also coming up with cheaper products that are acceptable in the regional markets. SLIT and subcutaneous immunotherapy (SCIT) are slowly being prescribed more as more and more providers realize the long-term advantages.

Competitive Landscape

The allergy immunotherapy market is highly competitive, with significant players including ALK-Abelló, Stallergenes Greer, HAL Allergy, Thermo Fisher Scientific, Medytox, Allergopharma, and Circassia Pharmaceuticals. ALK-Abelló and Stallergenes Greer are popular for sublingual and subcutaneous immunotherapy, and ALK-Abelló is moving forward with its oral immunotherapy solutions. Allergic Immunotherapy Tablets (AIT), another drug from Stallergenes Greer, are working effectively.

HAL Allergy has had increased success because of its tailored allergy treatment. The company's allergen-specific immunotherapy drugs position it well in the diagnostics industry. Circassia's transition to digital health solutions, and Medytox’s expansion into allergy immunotherapy, is recent advancements. The market is intense, with active R&D, approvals, and a shift towards non-intramuscular dosing approaches like sublingual tablets.

Allergy immunotherapy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2024, Viatris entered an agreement with Lexicon Pharmaceuticals for sotagliflozin, gaining rights to the drug in all markets outside the U.S. and Europe. Sotagliflozin, approved in May 2023, aims to reduce cardiovascular risks in patients with heart failure and type 2 diabetes. The deal includes a USD 25 million upfront payment and potential milestone payments, while Viatris will handle all regulatory and commercialization efforts.
• In September 2024, Merck and Siemens strengthened their partnership through a Memorandum of Understanding to enhance smart manufacturing, integrating advanced technologies for improved manufacturing processes. This collaboration aims to accelerate product development while prioritizing sustainability and flexibility through modular production.

Report Coverage:

By Product Type

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

• SLIT Tablets
• SLIT Drops

• Oral Immunotherapy (OIT)

By Allergy Type

• Allergic Rhinitis
• Asthma
• Food Allergy
• Atopic Dermatitis
• Venom Allergy

 By End-User

• Hospitals
• Clinics
• Homecare Setting

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• ALK-Abelló
• Stallergenes Greer
• HAL Allergy
• Thermo Fisher Scientific
• Medytox
• Allergopharma
• Circassia Pharmaceuticals
• HollisterStier Allergy
• Bayer AG
• BioClassified
• DBV Technologies
• Wolfe Laboratories
• Lofarma
• Immunotek
• R-Pharm

Frequently Asked Questions (FAQs)